Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Turcot syndrome 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 15Carboplatin 9liposomal doxorubicin 8Bevacizumab 8pembrolizumab 7Topotecan 6olaparib 4mirvetuximab soravtansine 4Nivolumab 4Cyclophosphamide 4niraparib 3fludarabine 3Gemcitabine 3Drug Therapy 3rucaparib 2ribociclib 2pegfilgrastim 2palbociclib 2oregovomab 2fludarabine phosphate 2Irinotecan 2Hyperthermic Intraperitoneal Chemotherapy 2Fulvestrant 2Cisplatin 2Blood Specimen Collection 21-dodecylpyridoxal 2trastuzumab deruxtecan 1sacituzumab govitecan 1isoquercitrin 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ovarian Epithelial × denileukin diftitox × 1 year × Clear all
NCT05200559 2026-05-29

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

University of Pittsburgh

Phase 1/2 Active not recruiting
25 enrolled
Gynecologic

Turcot syndrome, Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡